Global Long-acting Insulin Injection Market Growth 2025-2031
Description
The global Long-acting Insulin Injection market size is predicted to grow from US$ 19930 million in 2025 to US$ 21670 million in 2031; it is expected to grow at a CAGR of 1.4% from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Long-acting insulin injection refers to a type of insulin formulation designed to provide a slow, steady release of insulin over an extended period, typically up to 24 hours or more. It is used as basal insulin therapy to maintain consistent blood glucose levels between meals and overnight in patients with diabetes mellitus. This type of insulin reduces the number of daily injections and minimizes blood sugar fluctuations.
United States market for Long-acting Insulin Injection is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Long-acting Insulin Injection is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Long-acting Insulin Injection is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Long-acting Insulin Injection players cover Sanofi, Eli Lilly & Co, Biocon Biologics, Gan & Lee, Tonghua Dongbao, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Long-acting Insulin Injection Industry Forecast” looks at past sales and reviews total world Long-acting Insulin Injection sales in 2024, providing a comprehensive analysis by region and market sector of projected Long-acting Insulin Injection sales for 2025 through 2031. With Long-acting Insulin Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Long-acting Insulin Injection industry.
This Insight Report provides a comprehensive analysis of the global Long-acting Insulin Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Long-acting Insulin Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Long-acting Insulin Injection market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Long-acting Insulin Injection and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Long-acting Insulin Injection.
This report presents a comprehensive overview, market shares, and growth opportunities of Long-acting Insulin Injection market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Insulin Degludec
Insulin Detemir
Insulin Glargine
Segmentation by Application:
Type 1 Diabetes
Type 2 Diabetes
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Sanofi
Eli Lilly & Co
Biocon Biologics
Gan & Lee
Tonghua Dongbao
Biocare
United Laboratories
KALBE PHARMA
Swixx Biopharma
INFION PHARMA
Viatris
Wockhardt
Lupin Laboratories
Cipla
Novo Nordisk
Abbott Laboratories
Key Questions Addressed in this Report
What is the 10-year outlook for the global Long-acting Insulin Injection market?
What factors are driving Long-acting Insulin Injection market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Long-acting Insulin Injection market opportunities vary by end market size?
How does Long-acting Insulin Injection break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Long-acting insulin injection refers to a type of insulin formulation designed to provide a slow, steady release of insulin over an extended period, typically up to 24 hours or more. It is used as basal insulin therapy to maintain consistent blood glucose levels between meals and overnight in patients with diabetes mellitus. This type of insulin reduces the number of daily injections and minimizes blood sugar fluctuations.
United States market for Long-acting Insulin Injection is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Long-acting Insulin Injection is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Long-acting Insulin Injection is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Long-acting Insulin Injection players cover Sanofi, Eli Lilly & Co, Biocon Biologics, Gan & Lee, Tonghua Dongbao, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Long-acting Insulin Injection Industry Forecast” looks at past sales and reviews total world Long-acting Insulin Injection sales in 2024, providing a comprehensive analysis by region and market sector of projected Long-acting Insulin Injection sales for 2025 through 2031. With Long-acting Insulin Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Long-acting Insulin Injection industry.
This Insight Report provides a comprehensive analysis of the global Long-acting Insulin Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Long-acting Insulin Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Long-acting Insulin Injection market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Long-acting Insulin Injection and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Long-acting Insulin Injection.
This report presents a comprehensive overview, market shares, and growth opportunities of Long-acting Insulin Injection market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Insulin Degludec
Insulin Detemir
Insulin Glargine
Segmentation by Application:
Type 1 Diabetes
Type 2 Diabetes
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Sanofi
Eli Lilly & Co
Biocon Biologics
Gan & Lee
Tonghua Dongbao
Biocare
United Laboratories
KALBE PHARMA
Swixx Biopharma
INFION PHARMA
Viatris
Wockhardt
Lupin Laboratories
Cipla
Novo Nordisk
Abbott Laboratories
Key Questions Addressed in this Report
What is the 10-year outlook for the global Long-acting Insulin Injection market?
What factors are driving Long-acting Insulin Injection market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Long-acting Insulin Injection market opportunities vary by end market size?
How does Long-acting Insulin Injection break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
145 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Long-acting Insulin Injection by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Long-acting Insulin Injection by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
